{"preliminary_commentary":{"by_channel":{"x_thread":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"HEROEX-1","nct_id":"NCT06521554","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=heroex-1-nct06521554. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"NVL-330 oral daily dosing","label":"Phase 1a dose escalation","type":"EXPERIMENTAL"},{"description":"NVL-330 oral daily dosing","label":"Phase 1b dose expansion","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-02","type":"ESTIMATED"},"conditions":["Locally Advanced Solid Tumor","Metastatic Solid Tumor"],"enrollment":{"count":200,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"NVL-330","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-20","lead_sponsor":"Nuvalent Inc.","official_title":"A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Recommended Phase 2 Dose (RP2D)","timeFrame":"As determined by incidence of DLTs during the first 28 days of treatment (ie, Cycle 1)"},{"measure":"Maximum Tolerated Dose (MTD)","timeFrame":"As determined by incidence of DLTs during the first 28 days of treatment (ie, Cycle 1)"},{"measure":"Incidence and severity of Treatment Emergent Adverse Events (TEAEs)","timeFrame":"First dose of study drug through 30 days after the last dose of study drug"}],"references":[],"start_date":{"date":"2024-07-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)","url":"https://clinicaltrials.gov/study/NCT06521554"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/heroex-1-nct06521554"}